Defibrotide for the prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: A systematic review

Clinical Transplantation

Volumn 26, Issue 4, 2012, Pages 511-519

  Zhang, Lifei ^a   Wang, Yebo ^a   Huang, He ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Defibrotide; Hematopoietic stem cell transplantation; Prevention; Systematic review; Veno occlusive disease

Indexed keywords

AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; DEFIBROTIDE; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HEPARIN; HYDROXYUREA; MELPHALAN; METHYLPREDNISOLONE; THIOTEPA; THYMOCYTE ANTIBODY; TINZAPARIN; URSODEOXYCHOLIC ACID;

ALBERS SCHOENBERG DISEASE; ARTICLE; BLEEDING; DISEASE SEVERITY; DRUG SAFETY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; MALIGNANT INFANTILE OSTEOPETROSIS; META ANALYSIS; MORBIDITY; MORTALITY; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCED INTENSITY CONDITIONING; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; POLYDEOXYRIBONUCLEOTIDES;

EID: 84864959379     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2012.01604.x     Document Type: Article

References (33)

1. Coppell JA, Richardson PG, Soiffer R et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant 2010: 16: 157.
2. Wadleigh M, Richardson PG, Zahrieh D et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003: 102: 1578.
3. McKoy JM, Angelotta C, Bennett CL et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007: 31: 599.
4. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995: 85: 3005.
5. Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994: 19: 1171.
6. McDonald GB, Sharma P, Matthews DE et al. Venoclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984: 4: 116.
7. Jones RJ, Lee KS, Beschorner WE et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987: 44: 778.
8. Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant 2008: 41: 229.
9. Bearman SI, Lee JL, Barón AE, McDonald GB. Treatment of hepatic veno-occlusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997: 89: 1501.
10. Haussmann U, Fischer J, Eber S et al. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of preemptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica 2006: 91: 795.
11. Bearman SI, Shen DD, Hinds MS et al. A phase I/II study of prostaglandin E1 for the prevention of hepatic veno-occlusive disease after bone marrow transplantation. Br J Haematol 1993: 84: 724.
12. Morabito F, Gentile M, Gay F et al. Insights into defibrotide: an updated review. Expert Opin Biol Ther 2009: 9: 763.
13. Richardson PG, Elias AD, Krishnan A et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998: 92: 737.
14. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996: 17: 1.
15. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001: 323: 42.
16. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa, ON: The Ottawa Health Research Institute, University of Ottawa, 2005. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
17. Gardner M, Altman DG. Statistics with Confidence. Tavistock Square, London, UK: Wiley Blackwell, 1989: 6.
18. Corbacioglu S, Cesaro S, Faraci M et al. Defibrotide (DF) for the prevention of hepatic veno-occlusive disease (VOD) in pediatric stem cell trans-plantation: results of a prospective randomized phase II/III, multicenter trial. Eur J Pediatr 2010: 169: 380.
19. Qureshi A, Marshall L, Lancaster D. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children. Pediatr Blood Cancer 2008: 50: 831.
20. Corbacioglu S, Hönig M, Lahr G et al. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplant 2006: 38: 547.
21. Hasenkamp J, Conradi I, Wulf G et al. Prevention of veno-occlusive disease in hematopoietic stem cell transplantation due to defibrotide prophylaxis. Blood 2004: 114: 322A.
22. Chalandon Y, Roosnek E, Mermillod B et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004: 10: 347.
23. Cappelli B, Chiesa R, Evangelio C et al. Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan. Br J Haematol 2009: 147: 554.
24. Gray JC, Marshall L, Qureshi A et al. Defibrotide as prophylaxis for veno-occlusive disease in children undergoing allogenic and autologous stem cell transplantation. Bone Marrow Transplant 2008: 41: S298.
25. Bonini A, Tieghi A, Pilia A et al. Low-dose defibrotide after allogeneic stem cell transplantation as prophylaxis of veno-occlusive disease of the liver. A single-centre experience. Bone Marrow Transplant 2008: 41: S419.
26. Milone G, Poidomani M, Coppoletta S et al. Defibrotide in prevention of liver toxicity in patients at high risk of VOD after HSC transplantation. Blood 2008: 112: 1125.
27. Dignan F, Gujral D, Ethell M et al. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplant 2007: 40: 79.
28. Chalandon Y, Roosnek E, Helg C et al. Efficient prevention of veno-occlusive disease of the liver with defibrotide after allogeneic haematopoietic stem cell transplantation. An extended study. Bone Marrow Transplant 2007: 39: S197.
29. Versluys B, Bhattacharaya R, Steward C et al. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood 2004: 103: 1968.
30. Joshi R, Kerridge I, Grace S et al. Prophylactic defibrotide for the prevention of hepatic veno-occlusive disease (VOD) in hematopoietic stem cell transplantation (HSCT). Blood 2002: 100: 413A.
31. Ferrari PA, Cornelli U, Dina F, Gerosa C, Nazzari M, Ratti G. Defibrotide in the prevention of deep venous thrombosis in general surgery. Preliminary results of a multicenter study. Minerva Med 1988: 79: 551.
32. Violi F, Marubini E, Coccheri S, Nenci GG. Improvement of walking distance by defibrotide in patients with intermittent claudication-results of a randomized, placebo-controlled study (the DICLIS study). Defibrotide Intermittent CLaudication Italian Study. Thromb Haemost 2000: 83: 672.
33. Euser AM, Zoccali C, Jager KJ, Dekker FW. Cohort studies: prospective versus retrospective. Nephron Clin Pract 2009: 113: 214.